Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chembio Wins $13.2M US BARDA Contract To Develop POC Zika Tests

Executive Summary

HHS and its subagency Biomedical Advanced Research and Development Authority (BARDA) has put together additional funding to award Chembio Diagnostic Systems $13.2m to develop and commercialize the firm's rapid point-of-care Zika test, a mere two weeks after the agency said it only had enough funds for Zika vaccine development.

You may also be interested in...



Hologic Wins $4.1m To Advance Zika Blood Screen

The US Biomedical Advanced Research and Development Authority (BARDA) recently granted $4.1m to Hologic to advance development of a blood screen to detect Zika in the blood supply. Also, lawmakers are asking more questions about readiness in the US for detecting emerging infectious diseases and bioterrorism-related toxins.

House-Senate Conferees Fight Over Zika Funds As FDA Approves More Assays

Emergency funding to battle the summer's mosquito-borne Zika threat is trapped in a military/VA spending bill. Conferees must find a compromise between the House's $622m bid and the Senate's $1.1b offer in the thin stretch of time when both chambers will be session before they adjourn on July 15. In the interim, FDA has authorized more Zika tests.

White House To Deliver 25 Million Face Masks To Low-Income Americans

The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT103761

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel